Form 4: Tandem Diabetes Care EVP Shannon Hansen Reports Stock Transactions
SEC Form 4 Filing
Shannon Marie Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On May 15, 2025, Shannon Marie Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions involving common stock and restricted stock units (RSUs).
- Hansen acquired shares through the vesting of RSUs and had shares withheld by the company to cover tax obligations.
- Specifically, 531, 1,437 and 4,387 RSUs vested, resulting in the acquisition of the same number of common stock shares.
- The company withheld 190, 515 and 1,570 shares respectively at a price of $22.7 to satisfy tax withholding requirements.
- Following these transactions, Hansen directly owns 16,742 shares of common stock and indirectly owns 1,935 shares through the Shannon M. Hansen Trust.
- She also directly owns 1,592, 5,748 and 8,774 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral filing reflecting routine stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Positives
- The vesting of RSUs indicates that Hansen is meeting the conditions of her equity compensation plan.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies within the medical device industry.
Comparison to Industry Standards
- Executive compensation packages including RSUs are standard practice among publicly traded companies, including Tandem Diabetes Care's competitors like Insulet (PODD) and Dexcom (DXCM).
- The vesting schedules and tax withholding practices are generally consistent with industry norms for equity compensation.
- Similar filings are regularly made by executives at comparable companies, reflecting the ongoing management of equity-based compensation.
Stakeholder Impact
- The transactions have a minimal direct impact on shareholders, employees, customers, suppliers, or creditors.
- The filing provides transparency regarding executive compensation, which can influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| July 8, 2003 | Date of the Shannon M. Hansen Trust |
| February 15, 2022 | Date of RSU award pursuant to the 2013 Stock Incentive Plan |
| February 15, 2023 | First vesting date (25%) for RSUs awarded on February 15, 2022 |
| May 25, 2023 | Date of RSU award pursuant to the 2023 Long-Term Incentive Plan |
| May 15, 2024 | First vesting date (33%) for RSUs awarded on May 25, 2023 |
| May 23, 2024 | Date of RSU award pursuant to the 2023 Plan |
| May 15, 2025 | Date of reported transactions: vesting of RSUs and tax withholding |
| May 19, 2025 | Date of signature for the Form 4 filing |
Keywords
Tandem Diabetes Care, TNDM, Shannon Hansen, EVP & Chief Legal Officer, Form 4, Restricted Stock Units, RSU, Beneficial Ownership, Stock Transactions, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.